Advertisement
Research Topics
Subscribe to Research Topics
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Google's Next Business Venture: The Human Body

November 4, 2014 2:07 pm | by Ryan Bushey, Associate Editor | Articles | Comments

Google is working on a slew of ambitious projects that could drastically revolutionize healthcare as we know it. Read more...                       

Amgen's Trebananib Fails to Improve Survival in Phase 3 Ovarian Cancer Study

November 4, 2014 1:36 pm | News | Comments

Amgen announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer. Read more...              

FDA Study Reaffirms Safety and Efficacy Profile of Pradaxa

November 4, 2014 1:23 pm | News | Comments

An FDA study of more than 134,000 Medicare patients found that Pradaxa was associated with significantly reduced risks of ischemic stroke and intracranial hemorrhage and death. Read more...           

Advertisement

Startup's Technology Could Improve Cancer Drug Development

November 4, 2014 12:59 pm | News | Comments

Officials at a life sciences startup based on a Purdue University innovation said their technology could help pharmaceutical companies find more effective drug candidates and improve the results of personalized cancer care. Read more...    

Immunotherapy for Cancer Toxic with Obesity

November 4, 2014 11:51 am | News | Comments

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found. Read more...                 

Dana-Farber, Astellas Collaborate on Cancer Research

November 4, 2014 10:44 am | News | Comments

Dana-Farber Cancer Institute (Dana-Farber) and Astellas Pharma Inc. announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer. Read more...

Abide Collaborates With Oxford on Drug Targets

November 4, 2014 10:30 am | News | Comments

Abide Therapeutics announced that the company has entered into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, one of the largest enzyme classes with validated but under explored class of drug targets.  Read more...

Identifying New Drugs to Treat Lyme Disease

November 4, 2014 10:24 am | News | Comments

Researchers from the Johns Hopkins Bloomberg School of Public Health have developed a test they say will allow them to test thousands of FDA-approved drugs to see if they will work against the bacteria that causes tick-borne Lyme disease. Read more...

Advertisement

Using Real-World Data for Outcomes Research and Comparative Effectiveness Studies

November 4, 2014 10:17 am | by Christina Mack, Ph.D., MSPH, Associate Director, Epidemiology, Real-World & Late Phase Research, Quintiles, and Kathy Lang, Ph.D., Senior Director, Emerging Businesses Data & Analytics, Real-World & Late Phase Research, Quintiles | Articles | Comments

Biopharma is increasingly harnessing the power of data collected outside of a controlled clinical environment to generate valuable insights to support products throughout their lifecycle. Read more...

AstraZeneca, Definiens Deal Builds Cancer Immunotherapy Capability

November 4, 2014 10:05 am | News | Comments

AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumor tissue. Read more...

Scientists Try to Predict Number of U.S. Ebola Cases

November 3, 2014 3:04 pm | by Martha Mendoza – AP National Writer – Associated Press | News | Comments

Top medical experts studying the spread of Ebola say the public should expect more cases to emerge in the United States by year's end as infected people arrive here from West Africa, including American doctors and nurses returning from the hot zone and people fleeing from the deadly disease. Read more... 

Are My Muscular Dystrophy Drugs Working?

November 3, 2014 1:31 pm | News | Comments

People with muscular dystrophy could one day assess the effectiveness of their medication with the help of a smartphone-linked device, a new study in mice suggests.  Read more...                       

BDSI's Opioid Dependence Treatment Now Available in U.S.

November 3, 2014 1:23 pm | News | Comments

BioDelivery Sciences International, Inc.announced that Bunavail (buprenorphine and naloxone) buccal film (CIII) is now commercially available. Read more...                                               

Advertisement

Actavis, Durata Therapeutics Get FTC Clearance

November 3, 2014 1:08 pm | News | Comments

Actavis plc and Durata Therapeutics, Inc. announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to Actavis' pending acquisition of Durata. Read more...

Biosimilar Medications Could Create Billions in Savings

November 3, 2014 12:59 pm | News | Comments

Introducing competing “biosimilar” versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the United States by $44 billion over the next decade, according to new analysis from the RAND Corporation. Read more...

Nasal Spray Vaccine Could Protect Against Ebola Virus

November 3, 2014 12:44 pm | News | Comments

A nasal vaccine in development by researchers at The University of Texas at Austin has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Read more...

Researcher Debunks Alzheimer's Development Theory

November 3, 2014 12:36 pm | News | Comments

New research points to tau, not amyloid-beta (Abeta) plaque, as the seminal event that spurs neuron death in disorders such as Alzheimer's disease. The finding, which dramatically alters the prevailing theory of Alzheimer's development, also explains why some people with plaque build-up in their brains don't have dementia. Read more...

Inventiva Gains Positive Opinion for Orphan Drug Designation

November 3, 2014 11:20 am | News | Comments

Inventiva has received a positive opinion for a new orphan drug designation for systemic sclerosis. Read more...                         

Regulatory Data: Vital for DDI Risk-Mitigation Efforts

November 3, 2014 11:04 am | by Philip MacLaughlin, Product Director, PharmaPendium, Elsevier | Articles | Comments

Unanticipated adverse drug-drug interactions (DDIs) have led to the withdrawal of several high-profile drugs that had been available for a number of years, including terfenadine, astemizole, cisapride, grepafloxacin and mibefradil.  Read more... 

BMS Signs Exclusive Option for New Pulmonary Fibrosis Inhibitor

November 3, 2014 10:52 am | News | Comments

Bristol-Meyers Squibb and Galecto Biotech AB announced that the companies have entered into an agreement that provides BMS the exclusive option to acquire a a novel inhaled inhibitor for the treatment of idiopathic pulmonary fibrosis. Read more...  

Gates Foundation Boosts Aid to Stamp Out Malaria

November 3, 2014 9:11 am | by Marilynn Marchione - AP Chief Medical Writer | News | Comments

Philanthropist Bill Gates says he wants to end malaria in his lifetime and will give more money toward that goal. Read more...                       

The Man with a Thousand Brains

November 3, 2014 8:56 am | News | Comments

Forty million people worldwide are living with Alzheimer’s and this is only set to increase. But tiny brains grown in culture could help scientists learn more about this mysterious disease – and test new drugs. Read more...                          

First Human Clinical Trial of 'C dots' Highlights Safety

October 31, 2014 2:14 pm | News | Comments

A first clinical trial of these ultrasmall, multifunctional particles has deemed them safe for humans and cleared easily by the body. Read more...                   

Synthetic Lethality Offers New Approach to Kill Tumor Cells

October 31, 2014 1:51 pm | News | Comments

A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs. Read more...              

Mouse Model Could Accelerate Ebola Treatment Research

October 31, 2014 1:36 pm | News | Comments

Researchers at the University of North Carolina at Chapel Hill and colleagues have developed the first genetic strain of mice that can be infected with Ebola and display symptoms similar to those that humans experience. Read more...     

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading